HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kassis, S. Articles by Fishman, P. H. Search for Related Content PubMed PubMed Citation Articles by Kassis, S. Articles by Fishman, P. H. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 259, Issue 8, 4910-4916, 04, 1984

Induction of catecholamine-responsive adenylate cyclase in HeLa cells by sodium butyrate. Evidence for a more efficient stimulatory regulatory component

S Kassis, RC Henneberry and PH Fishman

HeLa cells, when exposed to 5 mM sodium butyrate, increased their responsiveness to isoproterenol and their number of beta-receptors. As untreated HeLa cells have a substantial number of receptors but respond poorly to isoproterenol, the effect of butyrate could be due to quantitative or qualitative changes in beta-receptors or other components of the adenylate cyclase system. Receptors were analyzed by membrane/membrane and membrane/cell fusion techniques. HeLa donor membranes, treated to inactivate regulatory and catalytic components of adenylate cyclase, were fused with Fc cells, which lack beta-receptors. Isoproterenol-stimulated adenylate cyclase activity in the fusates was proportional to the number of receptors present. There appeared to be only quantitative but not qualitative differences in beta-receptors from control and butyrate-treated HeLa. Prostaglandin E1 receptors from neuroblastoma cell membranes were similarly coupled to HeLa adenylate cyclase. The hybrid prostaglandin E1-stimulated activity was lower when acceptor membranes were from control HeLa than when they were from butyrate-treated HeLa cells. These results suggested that butyrate was altering the ability of the regulatory component to interact with receptors. HeLa membranes were extracted with sodium cholate and the extracts used to reconstitute effector-stimulated adenylate cyclase activity in S49 cyc- membranes, which lack a functional regulatory component. Whereas extracts from control and butyrate-treated HeLa were equally effective in restoring NaF-stimulated activity in cyc- membranes, extracts from control HeLa were less efficient in reconstituting isoproterenol- and prostaglandin E1-stimulated activities. We conclude that the poor response of control HeLa to beta- agonists is due to a limited activity of the regulatory component but not the receptor. Butyrate induces quantitative changes in the receptor and qualitative changes in the regulatory component that facilitate its ability to couple to receptors but do not alter its ability to interact with the catalytic component of adenylate cyclase.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Tahtaoui, M.-N. Balestre, P. Klotz, D. Rognan, C. Barberis, B. Mouillac, and M. Hibert Identification of the Binding Sites of the SR49059 Nonpeptide Antagonist into the V1a Vasopressin Receptor Using Sulfydryl-reactive Ligands and Cysteine Mutants as Chemical Sensors J. Biol. Chem., October 10, 2003; 278(41): 40010 - 40019. [Abstract] [Full Text] [PDF]

				S. Phalipou, R. Seyer, N. Cotte, C. Breton, C. Barberis, M. Hibert, and B. Mouillac Docking of Linear Peptide Antagonists into the Human V1a Vasopressin Receptor. IDENTIFICATION OF BINDING DOMAINS BY PHOTOAFFINITY LABELING J. Biol. Chem., August 13, 1999; 274(33): 23316 - 23327. [Abstract] [Full Text] [PDF]

				S. Phalipou, N. Cotte, E. Carnazzi, R. Seyer, E. Mahe, S. Jard, C. Barberis, and B. Mouillac Mapping Peptide-binding Domains of the Human V1a Vasopressin Receptor with a Photoactivatable Linear Peptide Antagonist J. Biol. Chem., October 17, 1997; 272(42): 26536 - 26544. [Abstract] [Full Text] [PDF]

				D. R. Warner, P. V. Gejman, R. M. Collins, and L. S. Weinstein A Novel Mutation Adjacent to the Switch III Domain of Gs{alpha} in a Patient with Pseudohypoparathyroidism Mol. Endocrinol., October 1, 1997; 11(11): 1718 - 1727. [Abstract] [Full Text]

				C. Breton, H. Chellil, M. Kabbaj-Benmansour, E. Carnazzi, R. Seyer, S. Phalipou, D. Morin, T. Durroux, H. Zingg, C. Barberis, et al. Direct Identification of Human Oxytocin Receptor-binding Domains Using a Photoactivatable Cyclic Peptide Antagonist. COMPARISON WITH THE HUMAN V1a VASOPRESSIN RECEPTOR J. Biol. Chem., July 13, 2001; 276(29): 26931 - 26941. [Abstract] [Full Text] [PDF]